Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: margie who wrote (4952)	7/22/1998 2:40:00 PM
From: Intel Trader	Respond to of 6136

Thank you margie. <eom>

To: margie who wrote (4952)	7/22/1998 2:51:00 PM
From: Biomaven	Read Replies (2) \| Respond to of 6136

Sounds like the model Rick proposed - a tax-free spin-off of the oncology division to shareholders - is what they are contemplating. If they fund it themselves, it is not dilutive. Shareholders would own exactly the same package as before, provided they continue to hold both stocks. Hard to know if it will have any effect on total market cap. The theory is that the parts are worth more than the whole, which may have some validity, in that potential shareholders get more choice as to what they want to hold. More interesting, to my mind, is what will happen to the shorts. They have to borrow the new shares that are being spun off and the logistics of this might produce a squeeze. In any event, they may think the risks of a squeeze are enough to close out the short for while. Certainly this is what I would do if I were short (which I am not). Peter